Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections - PubMed
3 hours ago
- #CRE
- #antimicrobial resistance
- #carbapenemases
- 30-day mortality rates were similar between patients treated with ceftazidime-avibactam and meropenem-vaborbactam for KPC-producing Enterobacterales infections.
- Emergence of resistance was higher in the ceftazidime-avibactam group (12%) compared to the meropenem-vaborbactam group (0%).
- Putative resistance mechanisms included porin mutations in Klebsiella pneumoniae and R2 loop structural changes in AmpC for Enterobacter cloacae complex.